Pages that link to "Q33964687"

The following pages link to A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease (Q33964687):

Displaying 43 items.

• The cybernetics of TNF: Old views and newer ones (Q26782229) (← links)
• Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. (Q33886907) (← links)
• Prognostic value of response after upfront therapy for acute GVHD (Q33964701) (← links)
• Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. (Q34487408) (← links)
• Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. (Q34551192) (← links)
• Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD (Q34974093) (← links)
• First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation (Q36113205) (← links)
• Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials (Q36321264) (← links)
• Implications of TNF-α in the pathogenesis and management of GVHD (Q36370782) (← links)
• Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? (Q37035815) (← links)
• Advances in the treatment of acute graft-versus-host disease. (Q37191057) (← links)
• Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials (Q37302887) (← links)
• Treatment and management of graft-versus-host disease: improving response and survival (Q37371836) (← links)
• Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins (Q37810286) (← links)
• The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation. (Q37851519) (← links)
• Cutaneous graft-versus-host disease: rationales and treatment options (Q37853600) (← links)
• Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease (Q37993979) (← links)
• Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation (Q38066586) (← links)
• Thinking out of the box--new approaches to controlling GVHD. (Q38175862) (← links)
• Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies (Q38226527) (← links)
• Prophylactic and therapeutic treatment of graft-versus-host disease in Japan (Q38416371) (← links)
• State-of-the-art acute and chronic GVHD treatment (Q38416376) (← links)
• Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease (Q38460376) (← links)
• The continuing evolution of targeted therapy for inflammatory skin disease (Q38596134) (← links)
• Cellular and molecular mechanisms in graft-versus-host disease (Q38661579) (← links)
• Graft Versus Host Disease After Liver Transplantation in Adults: A Case series, Review of Literature, and an Approach to Management (Q38919897) (← links)
• Oral glutamine supplementation improves intestinal permeability dysfunction in a murine acute graft-vs.-host disease model (Q43716527) (← links)
• The role of infliximab on paracetamol-induced hepatotoxicity in rats (Q44654576) (← links)
• Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival. (Q48120485) (← links)
• Successful treatment with placenta-derived decidual stromal cells in a pediatric patient with life-threatening acute gastrointestinal graft-versus-host disease. (Q48281486) (← links)
• [Off-label use of infliximab]. (Q54710052) (← links)
• Advance in Targeted Immunotherapy for Graft-Versus-Host Disease. (Q54937398) (← links)
• Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology. (Q55386131) (← links)
• Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation (Q57176290) (← links)
• TLR7 ligand R848 prevents mouse graft-versus-host disease and cooperates with anti-IL-27 antibody for maximal protection and Treg upregulation (Q59352689) (← links)
• Response as an end point in treatment trials for acute GVHD (Q83399715) (← links)
• Biomarkers for GVHD prognosis (Q86944490) (← links)
• Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation (Q90029164) (← links)
• Therapeutic targets and emerging treatment options in gastrointestinal acute graft-versus-host disease (Q90601512) (← links)
• Graft-Versus-Host Disease After Liver Transplantation (Q90746936) (← links)
• Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation (Q92023470) (← links)
• Remicade® (infliximab): 20 years of contributions to science and medicine (Q92798584) (← links)
• Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease (Q99207677) (← links)